New pill targets aggressive tumors with genetic flaw
NCT ID NCT06710847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or with another cancer medicine, can shrink tumors and is safe. About 14 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Denver, Colorado, 80218, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
New York, New York, 10016, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19107, United States
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Shizuoka, 411-8777, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Tokyo, 135-8550, Japan
-
GSK Investigational Site
Amsterdam, 1066 CX, Netherlands
-
GSK Investigational Site
Daegu, 41404, South Korea
-
GSK Investigational Site
Gyeonggi-do, 10408, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Barcelona, 08023, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Málaga, 29010, Spain